Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218).
The invention described in this review (WO2013030218) relates to compounds based on the quinazolin-4-one scaffold, their process of preparation and applications to inhibit the ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug...
| Auteur principal: | |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
Informa Healthcare
2014
|